tetano
Editor, Senior Moderator
Infection
. 2021 Apr 6.
doi: 10.1007/s15010-021-01606-9. Online ahead of print.
CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity
Jan-Moritz Doehn[SUP] #[/SUP][SUP] 1 [/SUP], Christoph Tabeling[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Robert Biesen[SUP] 4 [/SUP], Jacopo Saccomanno[SUP] 1 [/SUP], Elena Madlung[SUP] 1 [/SUP], Eva Pappe[SUP] 1 [/SUP], Frieder Gabriel[SUP] 1 [/SUP], Florian Kurth[SUP] 1 5 [/SUP], Christian Meisel[SUP] 6 7 [/SUP], Victor M Corman[SUP] 8 9 [/SUP], Leif G Hanitsch[SUP] 6 [/SUP], Sascha Treskatsch[SUP] 10 [/SUP], Kathrin Heim[SUP] 1 [/SUP], Miriam S Stegemann[SUP] 1 [/SUP], Christoph Ruwwe-Gl?senkamp[SUP] 1 [/SUP], Holger C M?ller-Redetzky[SUP] 1 [/SUP], Alexander Uhrig[SUP] 1 [/SUP], Rajan Somasundaram[SUP] 11 [/SUP], Claudia Spies[SUP] 12 [/SUP], Horst von Bernuth[SUP] 13 [/SUP], J?rg Hofmann[SUP] 7 8 9 [/SUP], Christian Drosten[SUP] 8 9 [/SUP], Norbert Suttorp[SUP] 1 14 [/SUP], Martin Witzenrath[SUP] 1 2 14 [/SUP], Leif E Sander[SUP] 1 14 [/SUP], Ralf-Harto H?bner[SUP] 15 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Type I interferons are important in the defense of viral infections. Recently, neutralizing IgG auto-antibodies against type I interferons were found in patients with severe COVID-19 infection. Here, we analyzed expression of CD169/SIGLEC1, a well described downstream molecule in interferon signaling, and found increased monocytic CD169/SIGLEC1 expression levels in patients with mild, acute COVID-19, compared to patients with severe disease. We recommend further clinical studies to evaluate the value of CD169/SIGLEC1 expression in patients with COVID-19 with or without auto-antibodies against type I interferons.
Keywords: CD169; COVID-19; SARS-CoV-2; SIGLEC1; Type I interferons.
. 2021 Apr 6.
doi: 10.1007/s15010-021-01606-9. Online ahead of print.
CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity
Jan-Moritz Doehn[SUP] #[/SUP][SUP] 1 [/SUP], Christoph Tabeling[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Robert Biesen[SUP] 4 [/SUP], Jacopo Saccomanno[SUP] 1 [/SUP], Elena Madlung[SUP] 1 [/SUP], Eva Pappe[SUP] 1 [/SUP], Frieder Gabriel[SUP] 1 [/SUP], Florian Kurth[SUP] 1 5 [/SUP], Christian Meisel[SUP] 6 7 [/SUP], Victor M Corman[SUP] 8 9 [/SUP], Leif G Hanitsch[SUP] 6 [/SUP], Sascha Treskatsch[SUP] 10 [/SUP], Kathrin Heim[SUP] 1 [/SUP], Miriam S Stegemann[SUP] 1 [/SUP], Christoph Ruwwe-Gl?senkamp[SUP] 1 [/SUP], Holger C M?ller-Redetzky[SUP] 1 [/SUP], Alexander Uhrig[SUP] 1 [/SUP], Rajan Somasundaram[SUP] 11 [/SUP], Claudia Spies[SUP] 12 [/SUP], Horst von Bernuth[SUP] 13 [/SUP], J?rg Hofmann[SUP] 7 8 9 [/SUP], Christian Drosten[SUP] 8 9 [/SUP], Norbert Suttorp[SUP] 1 14 [/SUP], Martin Witzenrath[SUP] 1 2 14 [/SUP], Leif E Sander[SUP] 1 14 [/SUP], Ralf-Harto H?bner[SUP] 15 [/SUP]
Affiliations
- PMID: 33825125
- DOI: 10.1007/s15010-021-01606-9
Abstract
Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Type I interferons are important in the defense of viral infections. Recently, neutralizing IgG auto-antibodies against type I interferons were found in patients with severe COVID-19 infection. Here, we analyzed expression of CD169/SIGLEC1, a well described downstream molecule in interferon signaling, and found increased monocytic CD169/SIGLEC1 expression levels in patients with mild, acute COVID-19, compared to patients with severe disease. We recommend further clinical studies to evaluate the value of CD169/SIGLEC1 expression in patients with COVID-19 with or without auto-antibodies against type I interferons.
Keywords: CD169; COVID-19; SARS-CoV-2; SIGLEC1; Type I interferons.